Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Asparaginase-Based Treatments in Young and Older Adults With Acute Lymphoblastic Leukemia: Leveraging the Pediatric Experience
  • CME

Credits Available
Physicians: maximum of 2.0 AMA PRA Category 1 Credits
Released: January 24, 2022 Expiration: January 23, 2023
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Jazz Pharmaceuticals
Servier Pharmaceuticals
Servier Oncology Global Medical and Patient Affairs
Wendy Stock, MD
Program Director
Emily Curran, MD
Dan Douer, MD
person default
Scott Howard, MD, MSc
person default
Stephen P. Hunger, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Select asparaginase-based induction treatment for adolescent/young adult and adult patients, considering optimal dosing and treatment schedules
  • Identify clinical and silent hypersensitivity reactions to asparaginase therapies
  • Plan strategies to achieve continued and active asparaginase treatment, including activity level testing and premedication
  • Integrate expert recommendations and available data on re-exposure of currently available asparaginase treatments or recombinant asparaginase formulations
  • Consider the data and clinical experience in pediatric patients to aid in treatment decisions for adolescent/young adult and adult patients

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Wendy Stock, MD

Professor of Medicine
Section of Hematology/Oncology
Department of Medicine
The University of Chicago
Chicago, Illinois

Wendy Stock, MD, has disclosed that she has received consulting fees from Agios, Amgen, AstraZeneca, GlaxoSmithKline, Jazz, Kite, Kronos, Kura, MorphoSys, Newave, Pfizer, Pluristem, Servier, and Syndax and honoraria from Jazz and Pfizer.

Faculty

Emily Curran, MD

Assistant Professor
Division of Hematology/Oncology
University of Cincinnati Cancer Institute
Cincinnati, Ohio

Emily Curran, MD, has disclosed that she has received consulting fees from Amgen, Servier, and Tempus.
Dan Douer, MD

Division of Hematology
Keck School of Medicine
Los Angeles, California

Dan Douer, MD, has disclosed that he has received consulting fees from Amgen, Jazz, and Servier and fees for non-CME/CE services from Adaptive, Amgen, and Servier.
Scott Howard, MD, MSc

Professor
Department of Acute and Tertiary Care
The University of Tennessee Health Science Center
Memphis, Tennessee

Scott Howard, MD, MSc, has disclosed that he has received consulting fees from Cellworks, Sanofi, and Servier and fees for non-CME/CE services from Sanofi.
Stephen P. Hunger, MD

Chief, Division of Pediatric Oncology
Children’s Hospital of Philadelphia
Philadelphia, Pennsylvania

Stephen P. Hunger, MD, has disclosed that he has received consulting fees from Servier and has ownership interest in Amgen.

Staff

Rachael M. Andrie, PhD

Scientific Director

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.
Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustance has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has no relevant conflicts of interest to report.
Krista Marcello

Associate Director, Educational Strategy

Krista V. Marcello has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Lisa Kuhns, PhD
Lisa Kuhns, PhD, has disclosed that she has received other financial or material support from Alcresta Therapeutics, Primus Pharmaceuticals, Parnell Pharmaceuticals, bioMerieux, and Beckman Coulter.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for hematologists/oncologists and other health professionals that care for patients with acute lymphocytic leukemia.

Goal

The goal of this activity is to improve the knowledge and competence of learners to integrate currently available and emerging asparaginase therapies for treatment of acute lymphoblastic leukemia in young adolescent and adult patients.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 24, 2022, through January 23, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Asparaginase-Based Treatments in Young and Older Adults With Acute Lymphoblastic Leukemia: Leveraging the Pediatric Experience
  • CME

Loading...
Watch this on-demand webcast of a live CCO webinar where an expert panel discusses the optimal use of pediatric asparaginase regimens in the treatment of AYA and adult patients with ALL, including patient case discussions and practical guidance on strategies to support completion of therapy.
Wendy Stock, MD
Program Director
Emily Curran, MD
Dan Douer, MD
person default
Scott Howard, MD, MSc
person default
Stephen P. Hunger, MD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits
Released: January 24, 2022 Expiration: January 23, 2023

Related Content

Expert case-based text module on managing toxicities with BCL-2 and PI3K inhibitors in CLL, from Clinical Care Options (CCO)

Nichole Fisher Headshot Nichole Fisher, RN, BSN Nicole Lamanna, MD Anthony Perissinotti, PharmD, BCOP Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: May 19, 2022 Expired: May 18, 2023

Experts review key data for multiple myeloma at the 2021 hematology annual meeting, from Clinical Care Options (CCO)

Shaji K. Kumar, MD Sagar Lonial, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: May 12, 2022 Expired: May 11, 2023

Clinical Care Options (CCO): Expert review of key data in MDS and MPN from the 2021 ASH annual meeting

Amy E. DeZern, MD, MHS Srdan Verstovsek, MD, PhD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: May 11, 2022 Expired: May 10, 2023

Clinical Care Options (CCO): Experts John M. Burke, MD, and Peter Martin, MD, review key data in lymphomas and CLL presented at the 2021 American Society of Hematology Annual Meeting

John M. Burke, MD Peter Martin, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: May 10, 2022 Expired: May 9, 2023
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Jazz Pharmaceuticals
Servier Pharmaceuticals
Servier Oncology Global Medical and Patient Affairs

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings